EG - Everest Group, Ltd.
Everest Group (NYSE: EG - Get Free Report) is anticipated to announce its Q2 2026 results after the market closes on Wednesday, July 29th. Analysts expect the company to announce earnings of $14.52 per share and revenue of $3.9935 billion for the quarter. Investors may visit the the company's upcoming Q2 2026 earning overview page for
Dimensional Fund Advisors LP lessened its stake in shares of Everest Group, Ltd. (NYSE: EG) by 3.4% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 414,923 shares of the company's stock after selling 14,469 shares during the quarter. Dimensional Fund
EG's Q2 results are likely to reflect disciplined underwriting and higher investment income despite lower premiums and catastrophe losses.
PROVO, Utah--(BUSINESS WIRE)---- $GDOT #BaaS--Recognition underscores Green Dot's decades-long commitment to supporting the financial wellness of working Americans.
Bank of New York Mellon Corp lessened its position in Everest Group, Ltd. (NYSE: EG) by 0.8% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 215,504 shares of the company's stock after selling 1,767 shares during the period.
Everest Group (EG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
California Public Employees Retirement System cut its holdings in Everest Group, Ltd. (NYSE: EG) by 11.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 94,010 shares of the company's stock after selling 12,645 shares during the quarter. California Public Employees
NEW YORK--(BUSINESS WIRE)--Global digital services leader TP (formerly Teleperformance) today announced it has been named a Leader in Everest Group's Healthcare CXM Intelligent Operations PEAK Matrix® Assessment, reinforcing its position as a strategic partner for healthcare organizations navigating rising complexity, regulatory demands, and growing consumer expectations. Everest Group evaluated 24 providers in this year's assessment, with TP ranked among the top performers for delivering high-.
Everest Group's disciplined underwriting, specialty business growth, investment income and capital management support long-term growth, though catastrophe and geopolitical risks remain.
MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (NYSE: CTEV), a technology, data, and insights company focused on making healthcare more affordable and transparent, today announced it has been recognized as a Leader in the Everest Group Pre-payment Integrity Solutions PEAK Matrix® Assessment 2026. The recognition and ascent into the Leader category reflects Claritev's longstanding history and continued investment in technology-enabled payment integrity that helps health plans identify potent.
On July 02, 2026, Everest Group Ltd (EG) shares rose 3.2% to a current price of $371.35. This price reflects a strong upward trend, with the stock moving within
Everest Group delivered outstanding Q1-2026 results, with net income of $653M ($16.21/share) and a 16.8% ROE, underscoring robust earnings power. EG trades at a compelling valuation, generating $60–$65 annualized EPS while priced at $320–$360, with tangible book value near $407/share and a conservative $420/share target by Jan 2027. Despite competitive pressures and softening property catastrophe pricing, EG maintains structural discipline, focusing on profitability and selective capacity deployment.
HAMILTON, Bermuda--(BUSINESS WIRE)--Everest Group, Ltd. (“Everest”) (NYSE: EG) will hold its second quarter 2026 earnings conference call on Thursday, July 30, 2026, beginning at 8:00 am Eastern Time. Dial in details can be obtained by completing the registration form available at: https://dpregister.com/sreg/10209412/10411df5d80 The call can be accessed via a live, listen only webcast at www.investors.everestglobal.com where a replay of the call will also be available. Everest will release fin.
EG is benefiting from rising investment income, with portfolio growth and higher yields strengthening earnings alongside underwriting results.
FOLSOM, Calif.--(BUSINESS WIRE)-- #ContingentWorkforce--Magnit Global™, the global leader in contingent workforce management solutions, today announced its designation as a Leader in the 2026 Vendor Management System (VMS) PEAK Matrix® Assessment released by Everest Group. Magnit achieved Leader distinction in all regions measured: global, North America, and EMEA. In addition, Magnit was recognized as a Star Performer in EMEA for its year-over-year regional growth and positive client feedback. Everest Group's PEAK Ma.
HAMILTON, Bermuda--(BUSINESS WIRE)--Everest Group, Ltd. (“Everest” or “the Company”) (NYSE: EG), a global specialty (re)insurance leader, today announced that it has partnered with Stone Point Insurance Solutions to launch Annapurna Re Ltd. (“Annapurna”), a Bermuda-based casualty reinsurance sidecar. Funds managed by Stone Point will serve as the inaugural, anchor investors in this multi-year vehicle. As part of the transaction, Annapurna is expected to deploy approximately $600 million of thir.
Everest Group benefits from underwriting discipline, rising investment income and global expansion while returning significant capital to shareholders.
Travere Therapeutics said on Tuesday it has signed a licensing pact with privately held biotech Everest Medicines to develop and commercialize an experimental kidney disease drug in a deal worth up to $1.14 billion.
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that it has entered into an exclusive licensing and collaboration agreement with Everest Medicines for the development and commercialization of civorebrutinib (also known as EVER001), a potential best-in-class oral, covalent reversible Bruton's tyrosine kinase (BTK) inhibitor in all markets outside China and certain countries in East and Southeast Asia. “Civorebrutinib represents a strategic and complementary.
Everest Group (EG) reported earnings 30 days ago. What's next for the stock?